Overview

Cholecalciferol on Hemodialysis Patients

Status:
Completed

Trial end date:
2018-09-28

Target enrollment:
0

Participant gender:
All

Summary

- Screening the prevalence of vitamin D deficiency among Egyptian hemodialysis patients on a single center (Ain Shams University hospital). - Assessing the effect of the native type of vitamin D (Cholecalciferol) on replenishing its deficiency via extra-renal vitamin D receptors (VDR), among Egyptian hemodialysis patients. - Assessing the effect of cholecalciferol on vascular calcification among Egyptian hemodialysis patients. - Assessing the effect of cholecalciferol on Blood pressure, parathyroid hormone.

Phase:

Phase 2/Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Ain Shams University

Treatments:

Cholecalciferol
Ergocalciferols
Vitamin D
Vitamins

Criteria

Inclusion Criteria:

1. Both sexes aged between 18-75 years

2. Patients on HD greater than 3 months at least.

3. Stable clinical condition (no hospitalization in the previous 3 months)

4. Informed consent in accordance with the Declaration of Helsinki.

5. PTH level between 150 - 800 pg/ml.

Exclusion Criteria:

1. Hypersensitivity to cholecalciferol.

2. Participant in an another clinical trial within the past 4 weeks.

3. Judged to be unsuitable as a subject by the attending physician.

4. Pregnant or breastfeeding female